Is it worthwhile to conduct a randomized controlled trial of glaucoma screening in the united kingdom?

Abstract

Objectives: To assess the value of conducting a glaucoma screening randomized controlled trial in the UK. Methods: Decision model based economic evaluation and value of information analysis. Model derived from a previous health technology assessment. Model updated in terms of structure and parameter estimates with data from surveys, interviews with members of the public and health care providers and routine sources. Results: On average, across a range of ages of initiating screening (40-60 years), glaucoma prevalence (1-5%), screening uptake (30-100%), and the performance of current case finding, screening was not cost-effective at a £30,000 threshold per quality adjusted life year (QALY) fr..